PARIS – Six months after opening its first Biome digital innovation lab in San Francisco, the Swiss pharmaceutical company Novartis AG announces the opening of its first European digital innovation lab, located at the head office of its subsidiary in Rueil-Malmaison, France. The French hub Biome Paris boasts 250 square meters of space, allowing French or foreign-based startups to innovate and respond to specific challenges arising in the pharmaceutical sector. "It is a platform interface between ourselves as drug specialists, startups and internet giants. Biome Paris will make our treatments available to patients more quickly," Frédéric Collet, Novartis country president, France, told BioWorld MedTech.

PARIS – Six months after opening its first Biome digital innovation lab in San Francisco, Swiss pharma company Novartis AG announced the opening of its first European digital innovation lab, located at the head office of its subsidiary in Rueil-Malmaison, France. 

PARIS – The public-private university hospital consortium Dhune, from the Provence-Alpes-Côte d'Azur (PACA) region, reported the creation of a seed capital fund dedicated exclusively to life sciences, amounting to $112 million. "First [is] the [inaugural] specialized seed fund for a French region dedicated primarily to startups in the field of neurodegenerative disease, as well as health care," Olivier Blin, head of the clinical pharmacology and pharmacovigilance department at Marseille University Hospital, told BioWorld.

PARIS – Six months after floating on the Euronext stock exchange in Paris, Predilife SA from Villejuif, France, is launching the Mammorisk predictive test for breast cancer risk in Europe and the U.S. "Mammorisk is the first multi-criteria test to use data mining, allowing it to combine medical imaging, genetic profile and family history," Pierre Verdet, assistant managing director of Predilife, told BioWorld MedTech.